Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.

PHASE2CompletedINTERVENTIONAL
Enrollment

177

Participants

Timeline

Start Date

June 12, 2020

Primary Completion Date

November 17, 2020

Study Completion Date

November 17, 2020

Conditions
COVID-19
Interventions
DRUG

Acalabrutinib

Acalabrutinib- administered orally

Trial Locations (50)

1221

Research Site, Ciudad de Buenos Aires

1827

Research Site, Johannesburg

2193

Research Site, Johannesburg

6529

Research Site, George

7500

Research Site, Cape Town

14050

Research Site, D.F

15324

Research Site, Lima

20132

Research Site, Milan

34147

Research Site, Bakırköy

34214

Research Site, Istanbul

34760

Research Site, Umraniye

50937

Research Site, Cologne

60590

Research Site, Frankfurt

64461

Research Site, Monterrey

82131

Research Site, Gauting

94805

Research Site, Villejuif

110017

Research Site, New Delhi

111539

Research Site, Moscow

119992

Research Site, Moscow

123182

Research Site, Moscow

143442

Research Site, Moscow

183047

Research Site, Murmansk

560002

Research Site, Bangalore

3341643

Research Site, Curicó

3460001

Research Site, Talca

7500692

Research Site, Santiago

C1180AAX

Research Site, Ciudad de Buenos Aires

B1842

Research Site, Monte Grande

B1704

Research Site, Ramos Mejía

18618-687

Research Site, Botucatu

72145-450

Research Site, Brasillia

88036-800

Research Site, Florianópolis

90035-903

Research Site, Porto Alegre

91350-200

Research Site, Porto Alegre

14051-140

Research Site, Ribeirão Preto

40110-060

Research Site, Salvador

09715090

Research Site, São Bernardo do Campo

01308-050

Research Site, São Paulo

01327-001

Research Site, São Paulo

04004-030

Research Site, São Paulo

00168

Research Site, Roma

162-8655

Research Site, Shinjuku-ku

03103

Research Site, México

LIMA 11

Research Site, Lima

LIMA 1

Research Site, Lima

02-507

Research Site, Warsaw

04-141

Research Site, Warsaw

0157

Research Site, Pretoria

06800

Research Site, Ankara

Unknown

Research Site, Istanbul

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Acerta Pharma BV

INDUSTRY

lead

AstraZeneca

INDUSTRY

NCT04346199 - Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19. | Biotech Hunter | Biotech Hunter